Karuna Therapeutics

Youtube Subscribe

Open: 213.42 Close: 215.19 Change: 1.77

The stock market through the eyes of an AI: Karuna Therapeutics.

How much time have you spent trying to decide whether investing in Karuna Therapeutics? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Karuna Therapeutics are: …

Concept Map

Semantic Network

Stock Summary

Karuna Therapeutics, Inc. creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate includes KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for.

Today's Summary

Karuna Therapeutics Inc. stock jumps 42% after sharing promising Phase 3 data for its schizophrenia drug. CFO Troy Ignelzi Sells 9,000 Shares of Karuna. Insider sell: CFO Xponance Inc. raised its position in shares of Karuna Therapeutics, Inc. at the end of the most recent reporting period. CWM LLC lifted its position by 158.3% during the fourth quarter. Karuna Therapeutics recently released its quarterly earnings data on May 4th, revealing promising results that exceeded market expectations. The average 12-month target price among brokers who have covered the company in the past year is $275.44.

Today's News

Karuna Therapeutics Inc. stock jumps 42% after sharing promising Phase 3 data for its schizophrenia drug. CFO Troy Ignelzi Sells 9,000 Shares of Karuna. Insider sell: CFO Xponance Inc. raised its position in shares of Karuna Therapeutics, Inc. at the end of the most recent reporting period. CWM LLC lifted its position by 158.3% during the fourth quarter. Karuna Therapeutics recently released its quarterly earnings data on May 4th, revealing promising results that exceeded market expectations. The average 12-month target price among brokers who have covered the company in the past year is $275.44.

Stock Profile

"Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate includes KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of various peripheral tissues and dementia-related psychosis, including Alzheimer's disease. The company also focuses on developing other muscarinic-targeted drug candidates; and intends to develop lead candidature TRPC4/5 and KAR-2618 for the treatment of mood and anxiety disorders. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company, and Zai Lab (Shanghai) Co., Ltd; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics, Inc. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts."

Keywords

This document will help you to evaluate Karuna Therapeutics without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Karuna Therapeutics are: Karuna, Therapeutics, Inc, share, data, CFO, position, and the most common words in the summary are: therapeutic, state, united, pharmaceutical, pharma, bioscience, karuna, . One of the sentences in the summary was: Insider sell: CFO Xponance Inc. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #therapeutic #state #united #pharmaceutical #pharma #bioscience #karuna.

Read more →

Youtube Subscribe

---